IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
| Revenue (TTM) | $86.34M |
| Gross Profit (TTM) | $65.50M |
| EBITDA | $29.18M |
| Operating Margin | 31.20% |
| Return on Equity | 23.50% |
| Return on Assets | 15.60% |
| Revenue/Share (TTM) | $6.77 |
| Book Value | $7.96 |
| Price-to-Book | 10.93 |
| Price-to-Sales (TTM) | 12.88 |
| EV/Revenue | 12.29 |
| EV/EBITDA | 36.34 |
| Quarterly Earnings Growth (YoY) | -9.30% |
| Quarterly Revenue Growth (YoY) | 0.30% |
| Shares Outstanding | $12.79M |
| Float | $8.33M |
| % Insiders | 35.19% |
| % Institutions | 63.11% |
Volatility is currently contracting
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida.
IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IRMD and any ticker you trade — then tracks every position and per-strategy win rate.
